What do CA 125 and other antigens tell us about ovarian cancer biology?

C E Welander, Charles E. Welander, Welander CE
Acta obstetricia et gynecologica Scandinavica. Supplement · 1992 · doi:10.1111/j.1600-0412.1992.tb00012.x · PMID:1502896
review OA: closed public-domain-us
View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-09 ⓘ

CA 125, an antigen on a glycoprotein, is tumor-associated with serous ovarian cancers and correlates with gross tumor volume changes and chemotherapy response in known cases.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

CA 125 is an antigenic determinant on a high molecular weight glycoprotein. A monoclonal antibody has been produced which recognizes this, and allows us to measure the expression of CA 125 in serum. Tissue distribution of the CA 125 determinant is most commonly seen in serous tumors of the ovary, with highest levels in borderline and frankly malignant serous cystadenocarcinomas. Occasionally cancers of the breast, gastrointestinal tract, and kidney will show elevated levels of CA 125. Normal tissues which show varying levels of CA 125 include decidual tissue and structures derived from celomic epithelium. CA 125 is clearly tumor associated, but not tumor specific. Quantitative correlation of CA 125 levels with tumor volume has not been demonstrated. This observation limits the clinical usefulness of CA 125 as a screening tool, particularly in premenopausal patients who do not have a diagnosis of ovarian cancer. An undetectable level of CA 125 antigen does not rule out the presence of an early ovarian cancer. When CA 125 is used to monitor disease state in patients with known ovarian cancers (whose tumors do express CA 125), changes in levels of CA 125 do correlate with gross changes in tumor volume. Good prognostic significance is attributed to a rapid decline in CA 125 levels following induction chemotherapy in patients with advanced ovarian cancer. However, an undetectable serum level of CA 125 does not predict clinical cure for a patient with ovarian cancer. Further clinical studies continue in the use of CA 125 as a screening tool and as a means to monitor treatment responses of known ovarian cancer.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antigens, Tumor-Associated, Carbohydrate Biomarkers, Tumor Ovarian Neoplasms Antigens, Tumor-Associated, Carbohydrate Biomarkers, Tumor Endometriosis Endometriosis Endometriosis Female Humans Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Pelvic Neoplasms Pelvic Neoplasms Pelvic Neoplasms Reference Values Sensitivity and Specificity

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (35)

Source provenance

crossref
last seen: 2026-08-21T06:37:06.691771+00:00
europepmc
last seen: 2026-08-30T09:23:35.175841+00:00
pubmed
last seen: 2026-05-13T22:11:54.876058+00:00
unpaywall
last seen: 2026-09-01T06:29:04.589233+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine